ANT-GROUP/COMFORTDELGRO
9.6.2022 01:39:13 CEST | Business Wire | Press release
ComfortDelGro Taxi and Alipay+ today announced a partnership that enables mobile payments from Malaysia and South Korea, namely the Touch ‘n Go eWallet and Kakao Pay, to be accepted as cashless payment options in all its Comfort and CityCab taxis. Users of these mobile wallets can pay for the cab fare simply through the wallet apps without the need to exchange currency.
ComfortDelGro Taxi is Singapore’s largest taxi operator with a combined fleet of about 9,000 Comfort and CityCab taxis. Apart from cash payment, all ComfortDelGro Taxis currently support about 20 different cashless payment methods.
Introduced by Ant Group in 2020, Alipay+ is a suite of global cross-border digital payments and marketing solutions designed to enable businesses, especially small and medium-sized businesses, to process a wide range of mobile payment methods and reach 1 billion regional and global consumers, through one-time integration and simple technical adaption. Other leading e-wallets supported by Alipay+ include GCash (Philippines), TrueMoney (Thailand), Alipay HK (Hong Kong SAR, China) and more.
ComfortDelGro Taxi’s CEO, Mr Jackson Chia said of this partnership: “With Singapore reopening its borders, we are looking forward to having tourists come visit us. As such, our partnership with Alipay+ is a vital one as it allows cashless payment options such as Malaysia’s Touch ‘n Go eWallet and soon South Korea’s Kakao Pay available on board ComfortDelGro taxis, making it more convenient for both Malaysian and South Korean tourists to pay for taxi fares. This saves them the hassle of having to have ready cash in local currency as they are able to pay the fares upfront on their own Touch ‘n Go eWallet or Kakao Pay App.”
Speaking of the collaboration, Ms Cherry Huang, General Manager, Global Merchant Partnership, South and Southeast Asia, Ant Group said: “Transportation is an essential daily need; taxi of all modes of transportation is even more important especially to travelers. Through the support and collaboration with ComfortDelGro Taxi, we aim to deliver to all users of mobile payments supported by Alipay+ a seamless and smart digital travel experience in Singapore, where they can pay with mobile wallets they are familiar with.”
“This partnership also comes at a great time, as Singapore leads the way in opening up its borders and welcomes tourists back in the city state. We believe this is the perfect moment for tourists to reimagine travel experience post pandemic,” she added.
According to the Singapore Tourism Board, the number of visitors to Singapore in the first four months of 2022 has exceeded figures for the whole of 20211 . Malaysia is ranked #3 among the top countries where the most tourists are from. South Korea is also an important traveler source market for Singapore. In pre-COVID times, South Korea was ranked 9th out of the top 15 visitor source markets in 20192 .
As part of a promotional campaign to commemorate this new collaboration, Touch ‘n Go eWallet users can enjoy instant discounts of RM4 or RM6 off their total fare when they pay for their rides using their Touch ‘n Go eWallet App from today until 25 June 2022. The discounts will vary in different weeks and are limited to the first 300 transactions daily.
About Ant Group
Ant Group aims to create the infrastructure and platform to support the digital transformation of the service industry. It strives to enable all consumers and small and micro businesses to have equal access to financial and other services that are inclusive, green and sustainable.
Ant Group is the owner and operator of Alipay, the leading digital payment platform in China serving hundreds of millions of users, and connecting them with merchants and partner financial institutions that offer inclusive financial services and digital daily life services such as food delivery, transport, entertainment, and healthcare.
Ant Group has further introduced Alipay+, which provides global cross-border mobile payments and marketing solutions that connect merchant partners, especially small and medium-sized businesses, with mobile payments and other payment methods, for them to better serve their users and customers from all over the world.
About ComfortDelGro Corporation Limited
ComfortDelGro is one of the world’s largest land transport companies with a total fleet size of about 35,000 buses, taxis and rental vehicles. We also run 177km of light and heavy rail networks in Singapore and New Zealand. Our global operations span seven countries – Singapore, Australia, the United Kingdom, New Zealand, China, Ireland and Malaysia. In Singapore, the Group operates about 9,000 Comfort and CtyCab taxis. For more information, visit www.comfortdelgro.com .
1
Source: The Straits Times (https://www.straitstimes.com/singapore/jan-april-tourist-numbers-exceed-arrivals-for-whole-of-2021-with-easing-of-border-curbs
)
2
Source: Singapore Tourism Board (https://www.stb.gov.sg/content/stb/en/media-centre/media-releases/Singapore-Tourism-Board-and-Studio-Dragon-Corporation-forge-a-three-year-partnership-to-jointly-promote-Singapore-through-branded-content.html
)
View source version on businesswire.com: https://www.businesswire.com/news/home/20220608005843/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom